Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-4

price sensitivity is determined by ASX.
A non PYC holder reading that (if they in fact could) would not realise
a) that was the last step really to trip PYC up
b) the probability of success of the in human trial is of the order of 70-80% because of the nature of the eye, and the work done to date including eye in dish work essentially showing magnificence.
c) that RP11 has an almost certain revenue of over a billion $US in a few years, and minimal expenses, and the patients are already ready.
and most importantly imo
d) this is a signal for other large biotechs to perhaps partner to use our platform.

Lets see if the next week or 3 bring any change to the sentiment around this stock.